Weight loss drug ‘Ozempic’ approved for use in India: What we need to know about its health benefits and risks

India has officially approved the use of Ozempic (semaglutide), a once-a-week injection designed for adults with type 2 diabetes. Approved by the Central Drugs Standard Control Organisation (CDSCO), this drug has made headlines worldwide not just for diabetes management but also for its weight loss effects. As India faces rising rates of diabetes, Ozempic’s arrival is more than just a medical update, it could influence lifestyle choices for millions.

Here’s all we need to know about what this new development means, its potential benefits, risks, and lifestyle implications.

What exactly is Ozempic?

Ozempic is the brand name for semaglutide, part of a class of drugs called GLP-1 receptor analogues. According to ANI, “Semaglutide Injection (Ozempic@) is indicated for the treatment of Adults with Insufficiently Controlled Type 2 Diabetes Mellitus as an adjunct to Diet and Exercise.”

Simply put, it mimics a natural hormone in the body, helping to control blood sugar levels. Administered once a week, it’s designed to complement healthy eating and physical activity. Beyond diabetes, it has shown promise in supporting weight management, making it a unique option for those tackling both conditions.
How Ozempic works for blood sugar

Ozempic works in multiple ways:

  • Boosts insulin production when blood sugar rises.
  • Reduces glucagon secretion, which prevents unnecessary sugar release from the liver.
  • Slows gastric emptying, helping people feel full for longer.
  • India is often called the world’s diabetes capital, with millions struggling to manage type 2 diabetes.

Access to innovative drugs like Ozempic could significantly improve health outcomes. According to Vikrant Shrotriya, Managing Director of Novo Nordisk India, “We strive to introduce the best-in-class innovations for the people who need it the most.”

Benefits that stand out

Ozempic offers several benefits that go beyond basic blood sugar control:

Effective glycemic control: Helps maintain stable blood sugar levels, reducing diabetes complications.

Cardiovascular protection: Studies suggest that it reduces the risk of major heart problems, a major concern for Indian patients with diabetes.

Potential liver health boost: Early studies suggest benefits for fatty liver, a common issue in urban populations.
It’s not just a drug; it can subtly support lifestyle improvements by controlling cravings and helping maintain healthier eating habits.

Possible risks and side effects

No drug is without caution. Ozempic users have reported:

  • Nausea, vomiting, or stomach upset.
  • Risk of pancreatitis and gallbladder issues.
  • Kidney complications in some users.
  • Mood changes or anxiety in certain cases.

Related Posts

Alembic Pharma Secures USFDA Approval for Generic Synthroid Tablets

New Delhi: Alembic Pharmaceuticals has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Levothyroxine Sodium Tablets USP in…

STF busts fake meds racket spread across 6 states

Dehradun: Uttarakhand special task force (STF) on Friday busted an online fake medicine racket operating through a Facebook page that allegedly sold counterfeit drugs, including cancer medicines, at discounts of…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Alembic Pharma Secures USFDA Approval for Generic Synthroid Tablets

Alembic Pharma Secures USFDA Approval for Generic Synthroid Tablets

STF busts fake meds racket spread across 6 states

STF busts fake meds racket spread across 6 states

All the Way from Teeth to Tee: Hole in One

All the Way from Teeth to Tee: Hole in One

Zydus Lifesciences Q4FY26 net profit rises 9%

Zydus Lifesciences Q4FY26 net profit rises 9%

Chemists strike on May 20: Reasons behind today’s all-India strike

Chemists strike on May 20: Reasons behind today’s all-India strike

AbbVie loses patent plea for Hep C drug

AbbVie loses patent plea for Hep C drug